Skip to main content
. 2021 Oct 28;22(21):11641. doi: 10.3390/ijms222111641

Figure 5.

Figure 5

Determination of ISGs suppressing SARS-CoV-2 genomic RNA using siRNA. (A) Schematic of the experimental design of HeLa cells stably expressing SARS-CoV-2 subreplicon (3C5) treated with siRNA and IFN-α for 1 day each prior to luciferase and cell viability assays. (B) HeLa cells stably expressing SARS-CoV-2 subreplicon were treated with OAS1, 2, and 3 and ISG20 siRNA for 1 day, and then the cells were treated with 1000 IU/mL IFN-α for 1 day. Luciferase intensity (blue bars) and cell viability (orange line) were measured and are shown as % of control siRNA-treated DMSO control. Error bars indicate SD (n = 3). * p < 0.05 (two-tailed t-test).